thx - agree and i have zero interest just too high risk and the pipeline is otherwise unimpressive just interesting to note they may have a nice drug from the imclone pipeline that was probably ascribed little value. votrient only does a fraction of their sales in sarcoma (150M?) so it's not a huge opportunity, although if they get front line it could be sizeable still..
Market Data 
Markets 
AI
